Global Search | Novartis

Hide Filters

Showing 1189 results

Press Release / Jun 26, 2015

Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action

Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
Press Release / Jun 18, 2015

Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg

Glatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Sandoz has begun shipping to US customers…
Press Release / Jun 18, 2015

Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day

Strong progress on innovation across divisions Pharmaceuticals is building breadth and depth in seven franchises, including Oncology, where it is complementing leadership in targeted therapies and…
Press Release / Jun 16, 2015

Alcon receives European approval for new trifocal presbyopia-correcting intraocular lens for patients undergoing cataract surgery

Innovative AcrySof® IQ PanOptix® trifocal intraocular lens design to improve near to intermediate vision and increase independence from glasses More than three million cataract surgeries…
Press Release / Jun 13, 2015

Novartis presents new data from large European study reinforcing the benefit of first-line Tasigna® in newly-diagnosed patients with CML

Patients on Tasigna achieved rapid and high rates of molecular response with a very low rate of progression to advanced disease ENEST1st data confirm the favorable benefit/risk profile of…
Press Release / Jun 13, 2015

Novartis announces data show majority of patients with polycythemia vera treated with Jakavi® achieved long-term disease control

Preplanned analysis at 18 months demonstrate 80% of PV patients treated with Jakavi® (ruxolitinib) experienced a durable response for at least one year[1] In the study, 83% of patients in…
Press Release / Jun 12, 2015

Novartis data at EHA show increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma

Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an…
Press Release / Jun 12, 2015

Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia

Arzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…
Press Release / Jun 12, 2015

Novartis reports new analysis showing Xolair® improving quality of life by 78% for chronic spontaneous urticaria patients

New analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
Press Release / Jun 11, 2015

Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder

Promacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low…